Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1944-446X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer ; volume:34 ; number:1 ; day:16 ; month:6 ; year:2015 ; pages:41-49 ; date:1.2015
Chinese journal of cancer ; 34, Heft 1 (16.6.2015), 41-49, 1.2015
- Creator
-
López-Guerrero, José Antonio
Romero, Ignacio
Poveda, Andrés
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.5732/cjc.014.10278
- URN
-
urn:nbn:de:101:1-2021081720170996311172
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- López-Guerrero, José Antonio
- Romero, Ignacio
- Poveda, Andrés
- SpringerLink (Online service)
Other Objects (12)
Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer